Researchers identify two distinct tuberculosis subtypes – one has better prognosis than the other

For people who contract tuberculosis (TB), the course of the disease can vary significantly. Most people do not become ill after infection with Mycobacterium tuberculosis, the bacterium that causes the disease. However, people can develop chronic pneumonia and some also have disease in the lymph nodes, bones or the central nervous system. Some TB patients have suppressed and exhausted immune responses, while others have an overacting response that makes the condition worse.

Dr. Andrew DiNardo, assistant professor of medicine – infectious diseases at Baylor College of Medicine and Texas Children’s Hospital, and his colleagues have been investigating novel ways to better understand tuberculosis, an infectious disease that affects 1.7 billion people around the world, according to the Centers for Disease Control and Prevention.

“We conducted this research study under the assumption that tuberculosis is not a uniform disease, that there are many pathways by which a person could develop the condition and that the outcome depends on the immune response produced by the infected person,” DiNardo said. “Researchers in the field are looking for new therapies for the disease, as current therapies require six months of antibiotics,”

To identify new treatments, researchers have been studying the human immune response to tuberculosis bacteria to shed light on what it takes to build protective immunity against this disease.

This approach can lead to the development of personalized precision medicine therapies.

“The discovery of disease subtypes or endotypes based on gene expression profiles has revolutionized our understanding of cancer and tailored patient therapy. We hypothesized that a similar approach could identify distinct and clinically relevant tuberculosis endotypes, and the results exceeded our expectations,” said senior author Dr. Cristian Coarfa, associate professor of molecular and cellular biology at Baylor and member of Baylor’s Dan L Duncan Comprehensive Cancer Center.

Led by Coarfa, the team applied cutting-edge unbiased bioinformatic techniques to analyze large patient datasets to look at immune responses to tuberculosis and identified two main clusters or endotypes of the disease. They then investigated these specific endotypes in two different patient cohorts and found that one endotype had a higher risk of treatment failure and death than the other. Using computer models, they then predicted what types of drugs could be used to treat each tuberculosis endotype.

“When we compared different drugs as potential personalized therapy, we found that one therapy could be inconsequential or detrimental to one TB subtype, but beneficial to the other,” DiNardo said.

“The results of this study will pave the way for personalized therapies, with great potential to improve treatment outcomes for the deadliest of all bacterial infectious diseases,” adds Professor Jan Heyckendorf, a DZIF tuberculosis researcher from Borstel and Kiel and one of the study’s lead authors.

“Whereas gene expression or transcriptomic-based TB endotypes are already informative, future work will incorporate other informative ‘omics,’ such as metabolomics (metabolites present) and epigenomics or the regulation of gene expression via DNA methylation, leading to further refinement of endotypes and personalized therapy,” Coarfa said.

Researchers will now implement clinical trials to treat tuberculosis following a stratified personalized therapy approach, similar to the one that oncologists take when treating different subsets of cancers.

Find all the details of this study in the the European Respiratory Journal.

The following researchers also took part in the study Tanmay Gandhi, Sandra L. Grimm Kimal Rajapakshe, Tomoki Nishiguchi, Maja Reimann, H. Lester Kirchner, Jaqueline Kahari, Qiniso Dlamini, Christoph Lange, Torsten Goldmann, Sebastian Marwitz, DZIF-TB cohort study group, Abhimanyu, Jeffrey D. Cirillo, Stefan HE Kaufmann, Mihai G. Netea, Reinout van Crevel and Anna M. Mandalakas.The authors are affiliated with one or more of the following institutions: Baylor College of Medicine; Texas Children’s Hospital; German Center for Infection Research (DZIF); University of Lübeck; Baylor-Swaziland Children’s Foundation; Texas A&M Health Science Center, Bryan; Max Planck Institute for Infection Biology; Texas A&M University, College Station; Radboud University Medical Center; University of Bonn; Max Planck Institute for Biophysical Chemistry and University of Oxford.

The study was funded by NIAID (grant K23 AI141681-02), the Cancer Prevention Institute of Texas (CPRIT) grants (RP170005, RP200504 and RP210227), NIH/NIAID grants (1U19AI144297, R01AI14578), NIH/NCI P30 shared resource grant CA125123, and NIEHS grants (P30 ES030285 and P42 ES027725). Further support was provided by the German Center for Infection Research, the Texas A&M University System and National Institutes of Health grant AI104960, an ERC Advanced Grant (#833247), a Spinoza grant of the Netherlands Organization for Scientific Research,NIH grants (R01AI14578, R01AI137527, U01GH002278) and DoD grant W81XWH1910026.

 

By Ana María Rodríguez, Ph. D.